About Epoetin Alfa (EPREX)
Class: | Erythropoiesis-stimulating agent (ESA), Recombinant human erythropoietin.
Use: | Treatment of anemia associated with chronic kidney disease (CKD), anemia in cancer patients on chemotherapy, anemia related to zidovudine therapy in HIV-infected patients, and to reduce the need for allogeneic blood transfusions in certain surgical patients.
Adult dose: | The dose varies based on the indication. For CKD patients, the initial dose is typically 50 to 100 IU/kg three times per week intravenous
Drug Class
Erythropoiesis-stimulating agent (ESA), Recombinant human erythropoietin.
Uses & Indications
Treatment of anemia associated with chronic kidney disease (CKD), anemia in cancer patients on chemotherapy, anemia related to zidovudine therapy in HIV-infected patients, and to reduce the need for allogeneic blood transfusions in certain surgical patients.
Storage Requirements
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Keep the vial in the outer carton until ready to use.
Manufacturer & Packaging
Manufacturer: Cilag AG, SWITZERLAND
Package Size
(10,000 IU/ML) x 6's Pre-filled Syringes
Price & Supplier
Price in UAE: AED 2734.67
Dosage Information
Adult Dose
The dose varies based on the indication. For CKD patients, the initial dose is typically 50 to 100 IU/kg three times per week intravenously or subcutaneously. Dose adjustments are made based on hemoglobin response.
Pediatric Dose
For pediatric patients with CKD, the initial dose is usually 50 IU/kg intravenously or subcutaneously three times per week. Dose adjustments are made based on hemoglobin response.
Side Effects
Common side effects include hypertension, headache, joint pain, muscle pain, fever, dizziness, and injection site reactions.
Contraindications & Precautions
Contraindicated in patients with uncontrolled hypertension, known hypersensitivity to epoetin alfa or any component of the formulation, and in patients who develop pure red cell aplasia (PRCA) following treatment with any erythropoietin protein drugs.
Important Warnings
Increased risk of serious cardiovascular events, thromboembolic events, stroke, and mortality when administered to target a hemoglobin level greater than 11 g/dL. Monitor hemoglobin levels regularly. Use caution in patients with a history of cardiovascular disease or thromboembolic disorders.
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.